In a career spanning nearly 20 years, George has held senior positions in R&D and Business Development. In his most recent two positions, he has led business development functions at leading oncology companies. He has a strong record of closing significant in-licensing and M&A transactions.
George is currently Senior Vice President of Business Development for Celgene Corporation, where he is responsible for the full array of business development activities (identification & evaluation of opportunities, structuring & negotiating transactions, in-licensing, M&A, outlicensing, and alliance management). At Celgene, these activities are focused within the therapeutic areas of oncology and inflammation.
Prior to Celgene, George served as Vice President of Business Development, Licensing and Strategy for Novartis-Oncology. During his tenure at Novartis, George's group closed a significant number of collaboration agreements which bolstered the development pipeline. Earlier in his career, George held senior positions at Elan Pharmaceuticals and at Schwarz Pharma, where he led the effort to in-license rotigotine and lacosamide (both now approved agents). In most of his positions, George has served on the R&D and/or Corporate Leadership Teams.
George received a BA in Biology from the University of Virginia, a PhD in Genetics from the University of Wisconsin-Madison. He has spoken frequently at industry conferences and leading business schools on a variety of topics related to the collaborations within the biopharmaceutical industry.